Allianz Asset Management GmbH Takes $593,000 Position in LivaNova PLC (NASDAQ:LIVN)

Key Points

• Allianz Asset Management GmbH has invested approximately $593,000 in LivaNova PLC, acquiring 15,100 shares in the first quarter of the year.
• Several other hedge funds have also increased their holdings in LivaNova, with notable purchases including one by Foundry Partners LLC valued at about $3.8 million.
• LivaNova's stock has seen mixed analyst ratings, with target prices ranging from $55.00 to $64.00, and an average rating of "Buy".

Allianz Asset Management GmbH acquired a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 15,100 shares of the company's stock, valued at approximately $593,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LIVN. Freestone Grove Partners LP bought a new position in LivaNova during the fourth quarter valued at approximately $23,102,000. The Manufacturers Life Insurance Company raised its position in LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock valued at $25,303,000 after purchasing an additional 339,139 shares during the period. AQR Capital Management LLC raised its holdings in shares of LivaNova by 79.3% in the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after buying an additional 328,313 shares during the period. Vanguard Group Inc. raised its holdings in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after buying an additional 265,291 shares during the period. Finally, Capital Research Global Investors raised its holdings in shares of LivaNova by 19.1% in the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company's stock worth $74,690,000 after buying an additional 258,730 shares during the period. 97.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Barclays dropped their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a research report on Tuesday, May 20th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Stock Performance

NASDAQ:LIVN traded up $4.10 during mid-day trading on Wednesday, reaching $46.71. The stock had a trading volume of 799,893 shares, compared to its average volume of 703,275. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.37 and a current ratio of 1.58. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -11.42 and a beta of 0.92. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $57.35. The business has a 50 day simple moving average of $44.62 and a 200 day simple moving average of $42.79.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.